|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.64 USD | -3.02% |
|
-7.72% | +5.67% |
| 06-29 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| 06-16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 460M | -38.15% | -49.86% | -22.56% | -14.89% | 2.64x | |
| 14.34B | 31.41% | 34.05% | 16.13% | 12.48% | -1.09x | |
| 9.09B | 20.13% | 25.95% | 14.91% | 8.78% | -0x | |
| 3.95B | 31.29% | 39.94% | 17.59% | 11.33% | -0.18x | |
| 15.56B | 19.3% | 28.72% | 16.36% | 7.75% | 1.74x | |
| 9.89B | 13.07% | 28.69% | 7.39% | 4.5% | 0.68x | |
| 5.14B | 25.03% | 31.43% | 31.7% | 22.02% | -1.81x | |
| 1.94B | -145.16% | -158.13% | -28.87% | -21.31% | 2.03x | |
| 502M | -144.39% | -104.25% | - | -78.14% | -2.48x | |
| 3.06B | 1.69% | 28.34% | 14.97% | 0.67% | 0.88x | |
| 638M | -28.69% | -26.12% | -252.11% | -29.11% | 0.85x | |
| 3.22B | 10.83% | 12.71% | 5.94% | 4.79% | -1.97x | |
| 150M | 66.87% | 49.52% | 39.67% | 25.58% | 1.24x | |
| 389M | 52.64% | 41.45% | 18.91% | - | - | |
| 8.83B | 5.34% | 18.49% | 6.14% | 2.42% | 4.83x | |
| 377M | -20.63% | -36.18% | - | - | - | |
| 579M | 28.22% | 29.21% | 10.08% | - | -1.4x | |
| 260M | -21.9% | -25.8% | -3.3% | - | - | |
| 1.05B | 21.46% | 26.05% | 4.9% | 5.4% | - | |
| Average | 4.18B | -3.77% | -0.3% | -6.01% | -2.52% | 0.40x | |
| Weighted average by Cap. | 7.36B | 4.97% | 11.23% | 4.24% | 2.89% | 0.03x |
- Stock Market
- Stocks
- ZLAB Stock
- Sector Zai Lab Limited
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
